Curasight A/S

Equities

CURAS

DK0061295797

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
9.1 ^DKK	-8.82%		-9.45%	-48.73%

Apr. 16	Curasight A/S Announces Approval of Clinical Trial Application for Phase 2 Trial with uTRACE in Prostate Cancer Patients	CI
Apr. 12	Curasight A/S Announces Board Changes	CI

BioStock: Curasight cancels rights issue and evaluates alternative financing

March 13, 2024 at 03:16 am EDT

In mid February, Curasight announced a DKK 51.2 million rights issue to accelerate clinical development of uTREAT and uTRACE. Now, about a month later, the company has decided to cancel the rights issue and is evaluating alternative sources of financing. Following the announcment, the share price traded down.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/03/curasight-cancels-rights-issue-and-evaluates-alternative-financing/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/curasight/r/biostock--curasight-cancels-rights-issue-and-evaluates-alternative-financing,c3944920

Latest news about Curasight A/S

Curasight A/S Announces Approval of Clinical Trial Application for Phase 2 Trial with uTRACE in Prostate Cancer Patients	Apr. 16	CI
Curasight A/S Announces Board Changes	Apr. 12	CI
Curasight A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Curasight A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Curasight A/S Announces Acceleration of Therapeutic Strategy to Strengthen Position as A Radiopharmaceutical Theranostic Company	Feb. 13	CI
Curasight Gears Up for Phase II Study in Prostate Cancer	Dec. 22	CI
Curasight A/S Submits Clinical Trial Application for Phase 2 Trial with Utrace	Dec. 18	CI
Curasight A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 23	CI
Curasight A/S Reports Positive Preclinical Results with uTREAT[®] in lung cancer	23-10-18	CI
Curasight A/S Announces Positive Results from the Phase II Study of uTRACE in Brain Cancer Presented at the World Molecular Imaging Congress 2023 in Prague	23-09-14	CI
Curasight A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Curasight A/S Announces Positive Results in Upar-Pet/MR Phase II Study in Brain Cancer	23-06-29	CI
Curasight A/S Reports Positive Preclinical Results with uTREAT in Aggressive Brain Cancer (Glioblastoma)	23-06-07	CI
Curasight A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25	CI
Curasight Secures Global License Agreement for Utrace in Prostate Cancer	23-05-11	CI
Curasight A/S Enters into an Exclusive Global License and Collaboration Agreement with Curium Inc	23-05-01	CI
Curasight A/S Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-23	CI
Curasight A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-23	CI
Curasight A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-24	CI
Curasight A/S Initiates Pre-Clinical Studies with uTREAT Therapy in Head and Neck Cancer and Neuroendocrine Tumors	22-10-13	CI
Curasight A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-25	CI
Curasight A/S Announces Recruitment Completes in uPAR-PET Study in Brain Cancer	22-06-30	CI
Curasight A/S Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-24	CI
Curasight A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	22-02-24	CI
Curasight A/S Expands its Strategy and Strengthen its Position as a Theranostic Company	22-02-23	CI

Chart Curasight A/S

Duration

Period

More charts

Company Profile

Curasight A/S is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (uPAR). The technology provides improved diagnosis and risk stratification in multiple cancer types.

Sector

Biotechnology & Medical Research

Calendar

2024-05-22 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CURASIGHT A/S	-48.73%	25.92M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research